Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
C Alcalá, F Gascón, F Pérez-Miralles, S Gil-Perotín… - Journal of …, 2018 - Springer
Introduction Rituximab is considered as a potential therapeutic option in relapsing-remitting
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the …
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the …
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
C Alcalá, F Gascón, F Pérez-Miralles… - Journal of …, 2018 - search.proquest.com
Results A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All
patients had an active disease despite standard treatment. The annualized relapse rate …
patients had an active disease despite standard treatment. The annualized relapse rate …
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
C Alcalá, F Gascón, F Pérez-Miralles… - Journal of …, 2018 - search.ebscohost.com
Introduction: Rituximab is considered as a potential therapeutic option in relapsing-remitting
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective: To investigate …
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective: To investigate …
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
C Alcalá, F Gascón, F Pérez-Miralles… - Journal of …, 2018 - europepmc.org
Results A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All
patients had an active disease despite standard treatment. The annualized relapse rate …
patients had an active disease despite standard treatment. The annualized relapse rate …
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
C Alcalá, F Gascón, F Pérez-Miralles… - Journal of …, 2018 - pubmed.ncbi.nlm.nih.gov
Introduction Rituximab is considered as a potential therapeutic option in relapsing-remitting
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the …
(RRMS) and progressive forms (PMS) of multiple sclerosis (MS). Objective To investigate the …
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
C Alcalá, F Gascón, F Pérez-Miralles… - Journal of …, 2018 - search.proquest.com
Results A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All
patients had an active disease despite standard treatment. The annualized relapse rate …
patients had an active disease despite standard treatment. The annualized relapse rate …